Lerociclib is a small molecule commercialized by EQRx, with a leading Phase III program in Endometrial Cancer. According to Globaldata, it is involved in 11 clinical trials, of which 3 were completed, 6 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Lerociclib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Lerociclib is expected to reach an annual total of $58 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
lerociclib is under development for the treatment of estrogen-receptor positive, hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer, castrate-resistant prostate cancer, endometrial cancer and non-small cell lung cancer (NSCLC). The drug candidate is administered through oral route. It acts by targeting cyclin-dependent kinases (CDK) 4 and 6.
EQRx is a biotechnology company that focuses on creating novel patent-protected medicines at lower prices. The company’s pipeline products include Aumolertinib is for the treatment of adult patients with locally advanced or metastatic NSCLC, Lerociclib is for the treatment of retinoblastoma protein (Rb) positive cancers, Nofazinlimab for the treatment of liver cancer, EQ121 for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis, Sugemalima is for the treatment of Stage IV NSCLC or ENKTL, respectively in the United States. EQRx is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$355.9 million in FY2022, compared to an operating loss of US$196.4 million in FY2021. The net loss of the company was US$169.1 million in FY2022, compared to a net loss of US$100 million in FY2021.
For a complete picture of Lerociclib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.